Sochal M, Krzywdzińska M, Gabryelska A, et al. A simple index to predict the efficiency of adalimumab treatment in Crohn disease with a limited duration of therapy. Pol Arch Intern Med. 2020; 130: 910-912. doi:10.20452/pamw.15507

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. The baseline characteristics of patients included in the analysis with the subgroups of patients, who maintained 18 month remission or relapsed.

		Relapse	p	OR
				(95% CI)
47	23 (48.9)	24 (51.1)	NA	NA
18 (38.3)	10 (43.5)	8 (33.3)	0.48	0.7
				(0.2-2.1)
32.5	28.0	35.5	0.11	1.0
(25.5-45.5)	(23.0-29.0)	(29.5-49.5)		(0.97-1.1)
14 (29.8)	2 (8.7)	12 (50.0)	0.003	10.5
				(2.0-55.0)
17 (36.2)	4 (17.4)	13 (54.2)	0.02	5.6
				(1.5-21.5)
25 (53.2)	6 (26.1)	19 (79.2)	< 0.001	10.8
				(2.8-41.8)
7 (14.9)	4 (17.4)	3 (12.5)	0.70	0.7
	18 (38.3) 32.5 (25.5-45.5) 14 (29.8) 17 (36.2) 25 (53.2)	18 (38.3) 10 (43.5) 32.5 28.0 (25.5-45.5) (23.0-29.0) 14 (29.8) 2 (8.7) 17 (36.2) 4 (17.4) 25 (53.2) 6 (26.1)	18 (38.3) 10 (43.5) 8 (33.3) 32.5 28.0 35.5 (25.5-45.5) (23.0-29.0) (29.5-49.5) 14 (29.8) 2 (8.7) 12 (50.0) 17 (36.2) 4 (17.4) 13 (54.2) 25 (53.2) 6 (26.1) 19 (79.2)	18 (38.3) 10 (43.5) 8 (33.3) 0.48 32.5 28.0 35.5 0.11 (25.5-45.5) (23.0-29.0) (29.5-49.5) 14 (29.8) 2 (8.7) 12 (50.0) 0.003 17 (36.2) 4 (17.4) 13 (54.2) 0.02 25 (53.2) 6 (26.1) 19 (79.2) <0.001

					(0.1-3.4)
Other chronic diseases	18 (38.3)	6 (26.1)	12 (50.0)	0.09	2.8
(%)					(0.8-9.7)
PLT, G/L	344.0	320.0	347.0	0.57	1.0
(before therapy)	(260.0-434.0)	(260.0-385.0)	(258.5-446.0)		(0.997-
					1.0)
PLT, G/L	281.0	277.0	295.5	0.18	1.0
(after induction therapy)	(225.0-336.0)	(223.0-318.0)	(253.0-359.5)		(0.998-
					1.0)
MPV, fl	9.5 (8.9-10.1)	9.7 (9.4-10.5)	9.1 (8.9-9.9)	0.13	0.5
(before therapy)					(0.2-1.2)
MPV, fl	9.8 (9.1-10.6)	10.4 (9.4-11.1)	9.5 (9.0-10.1)	0.01	0.4
(after induction therapy)					(0.2-0.9)
MPV <10.4fl (%)	32 (68.1)	11 (47.8)	21 (87.5)	0.005	7.6
(after induction therapy)					(1.8-32.9)
WBC, G/L	8.1 (6.3-10.6)	7.9 (5.7-10.4)	9.9 (7.4-10.8)	0.18	1.2
(before therapy)					(0.9-1.4)
WBC, G/L	7.3 (5.4-9.0)	5.6 (5.1-7.8)	8.6 (5.8-10.3)	0.008	1.4
(after induction therapy)					(1.1-1.9)
WBC >7.9G/L (%)	20 (42.6)	5 (21.7)	15 (62.5)	0.008	6.0
(after induction therapy)					(1.7-21.8)

Data are presented as median (IQR) unless otherwise indicated.

^{*} i.e. fistulas, abscesses, fissures, intestinal stenosis and obstruction

CD: Crohn's disease, CI: confidence interval, MPV: mean platelet volume, N: number of participants, NA: not applicable, OR: odd ratio, PLT: platelets, WBC: white blood cells. P relates to the difference between remission and relapse groups.